The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Regulatory T cells and the immune compartment in pre-invasive lung lesions
James Reading, PhD, University College London, London, UK, discusses the identification of pre-invasive lesions in high-risk lung cancer patients and the characterization of the immune compartment within these lesions, revealing a subset of regulatory T cells that are potent immunosuppressive cells. Dr Reading highlights that targeting these regulatory T cells with a PI3Kδ inhibitor can dismantle the pre-invasive immune regulatory axis, leading to a significant reduction in lung tumor development in a mouse model, and that a prototype biomarker has been identified in the blood to track the formation of lung cancer and select patients who may benefit from Treg-targeted immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
